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Mammographic screening before age 50 years is less effective than at older ages and the associated radiation risks are higher. We
estimated how many breast cancer deaths could be caused and how many could be prevented by a decade of annual two-view
mammographic screening starting at ages 20, 30 and 40 years, respectively, in the UK; for all women, and for women with first-degree
relatives affected with breast cancer. We extrapolated from a radiation risk model to estimate the number of radiation-induced
breast cancer deaths, and used results from randomised trials, which suggest a reduction in breast cancer mortality of 10–20% in
women invited to screening before age 50 years, to estimate the number of deaths that could be prevented. The net change in breast
cancer deaths was defined as the number of radiation-induced deaths minus the number of prevented deaths. For all women,
assuming a reduction in mortality from screening of 20%, a decade of annual screening was estimated to induce more deaths than it
prevents if started at age 20 years and at age 30 years (net increase¼0.86 and 0.37 breast cancer deaths, respectively, per 1000
women screened). The corresponding estimate for screening starting at age 40 years was a net decrease of 0.46 deaths/1000 women
screened and a zero net change assuming a 10% mortality reduction. Results for women with first-degree relatives with breast cancer
were generally in the same direction but, because their background incidence rates are higher, the net increases or decreases were
greater. In conclusion, our estimates suggest that a decade of annual two-view mammographic screening before age 40 years would
result in a net increase in breast cancer deaths, and that starting at age 40 years could result in a material net decrease only if breast
cancer mortality is reduced by about 20% or more in women screened. Although these calculations were based on a number of
uncertain parameters, in general, the conclusions were not altered when these parameters were varied within a feasible range.
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The National Health Service Breast Screening Programme cur-
rently invites women in the UK aged 50–70 years for mammo-
graphic screening once every 3 years. Whether screening should be
offered to women younger than age 50 years, particularly to those
thought to be at a higher than average risk of the disease because
of a family history of breast cancer, is a question that is frequently
raised. However, mammographic screening before age 50 years is
less effective than at older ages possibly because premenopausal
women have denser breasts and because the tumours grow more
rapidly (Buist et al, 2004). Preliminary results from the UK Age
Trial suggest that the reduction in breast cancer mortality
associated with offering annual mammographic screening from
age 40 to 47/48 years may be 10% (Moss et al, 2005), which is
considerably lower than the 25% reduction achieved in rando-
mised trials offering regular screening to women aged 50–69 years
(IARC, 2002).
Exposure to mammographic X-rays confers a risk of radiation-
induced breast cancer, which is greater the younger the women are
when they are exposed (Preston et al, 2002). It is difficult to
quantify the risk of radiation-induced breast cancer associated
with the low doses of radiation to which women are exposed
during mammographic screening using observational studies
directly (Ron, 2003). However, the risks can be estimated by
extrapolating results from studies of populations exposed to a
wider range of radiation doses. In this paper, we estimate the
number of radiation-induced breast cancer deaths associated with
a decade of annual mammographic screening starting at ages 20,
30 and 40 years using results from a recent pooled analysis of
cohort studies of breast cancer risk after radiation exposure
(Preston et al, 2002). These estimates are then compared with the
estimated number of deaths from breast cancer that could be
prevented by mammographic screening assuming a 10 or 20%
reduction in mortality, respectively, in women screened. Results
are presented both for all women and for women who have first-
degree relatives affected with breast cancer.
MATERIALS AND METHODS
Number of radiation-induced breast cancer deaths
For our calculations, we assumed that before age 50 years women
would be screened annually with a two-view mammogram. Data
collected on a sample of women in the UK NHS Breast Screening
Programme during 2001–2002 and conversion factors for
glandular dose give estimates of an average radiation dose to the
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yglandular breast tissue of 4.5mGy from a two-view mammogram
(Dance et al, 1999; Young et al, 2005); we used this tissue dose and
assumed that the dose does not vary with age (Young, 2002).
Estimates of the risk of radiation-induced breast cancer
presented here were calculated using an excess relative risk model
(ERR), which means that the risk of radiation-induced breast
cancer is calculated relative to the estimated ‘underlying’ breast
cancer incidence rate for the UK population. The risk model that
was used was based on a pooled analysis of three cohort studies
from Preston et al (2002). Two of these three cohorts were
comprised of women with tuberculosis who had multiple
fluoroscopy examinations, and hence received very similar types
of radiation exposure to those under consideration here (i.e.
multiple diagnostic X-rays). The excess relative risk was found to
increase linearly with increasing radiation dose and to decrease
with increasing attained age. The underlying breast cancer rate
that was used was for 2001 and is an estimate of what the current
rate would be in the absence of breast cancer screening of women
aged 50 years and over (Moss, personal communication). Further
details on the model and methods used are provided in the
Appendix A.
The estimated risk of radiation-induced breast cancer mortality
was then estimated from the risk of radiation-induced breast
cancer incidence to enable a direct comparison with the number of
deaths that could be prevented by screening. We estimated current
age-specific breast cancer survival probabilities by taking the 10-
year relative survival probability in England and Wales for women
whose breast cancers were diagnosed between 1980 and 1985
(Coleman et al, 1999) and scaling it by the ratio of breast cancer
mortality rates in 1985 (ONS, 1986) to 2001 (ONS, 2002). This
resulted in estimates of current breast cancer survival probabilities
of 0.59 for diagnoses between ages 15 and 44 years, 0.65 for
diagnoses between ages 45 and 59 years and 0.54 for diagnoses at
age 60þ years. The estimated risk of radiation-induced breast
cancer incidence at each age was multiplied by 1 the age-specific
survival probability to calculate the risk of radiation-induced
breast cancer mortality.
Preston et al (2002) found that the incidence of breast cancer is
increased from about 10 years after initial radiation exposure and
remains elevated for at least 50–60 years after exposure. Therefore,
the total risk of radiation-induced breast cancer mortality was
estimated as a cumulative (lifetime) risk beginning from 10 years
after exposure and continuing up to age 85 years, with adjustment
for competing causes of death based on UK all cause mortality
rates for 2001 (ONS, 2002).
Number of breast cancer deaths prevented
Results from randomised trials suggest that, at a population level,
offering mammographic screening to women aged 50–69 years
could reduce breast cancer mortality by 25%, which implies a 35%
reduction in mortality among the women who attend regular
mammographic screening (IARC, 2002). A review of results from
the randomised trials of women aged 40–49 years when they were
first offered screening suggests a possible 20% reduction in breast
cancer mortality (IARC, 2002). However, this is considered to be
the maximum likely reduction as part of this reduction is likely to
be due to mammography performed after age 50 years in these
trials. Preliminary results (based on surrogate markers) from the
UK Age Trial, which was designed specifically to investigate the
effect of mammographic screening of women starting at age 40
years compared to starting at age 50 years, suggest that the
reduction in breast cancer mortality associated with offering
annual mammographic screening from ages 40 to 47/48 years may
be 10% (Moss et al, 2005). Therefore, the number of deaths that
could be prevented by a decade of annual screening for women
aged less than 50 years was calculated under two scenarios:
assuming, respectively, a 10 or 20% reduction in breast cancer
mortality among women screened.
In these calculations, it was necessary to take account of the fact
that the mortality reduction would only apply to deaths from
cancers that were diagnosed during the screening period. To
estimate the proportion of cancer deaths that would have been
diagnosed in each screening decade, data on the age at breast
cancer death were crossclassified by age at diagnosis for the deaths
in England and Wales in 1998 (M Quinn, personal communication).
The breast cancer mortality rates that could be reduced by
attending screening were then estimated by scaling the UK breast
cancer mortality rates for 2001 by the probabilities that the cancer
deaths at each age were diagnosed during the screening decade.
The number of breast cancer deaths that could be prevented by
attending screening was estimated by reducing these scaled rates
by 10 and 20%, respectively.
The net change in breast cancer mortality was defined as the
number of radiation-induced breast cancer deaths minus the
number of deaths that could be prevented per 1000 women
screened. A positive net change means that the radiation-induced
risks are greater than the mortality benefits and vice versa.
Sensitivity analyses were also performed to evaluate the effects
of uncertainties in the radiation risk models and mortality benefits
on the results.
Women with a family history of breast cancer
These calculations were repeated for women with first-degree
relatives with breast cancer by scaling the estimated underlying UK
breast cancer incidence rates and mortality rates by estimates of
risk ratios for breast cancer incidence and mortality for women
with a family history of breast cancer, compared with women who
had no family history of breast cancer. These risk ratios were taken
from results of a reanalysis of epidemiological studies of familial
breast cancer (Collaborative Group on Hormonal Factors in Breast
Cancer, 2001). For example, a woman with one affected first-degree
relative was assumed to have an underlying breast cancer
incidence rate at ages 45–54 years that was 1.9 times higher than
the breast cancer incidence rate in the general population, and for
a woman with two affected first-degree relatives the estimated rate
for those ages was 3.2 times higher than that in the general
population. All other aspects of the calculations were the same as
for the general population.
Years of life lost and gained
Since the radiation-induced cancers are likely to occur later in life,
on average, than the deaths that are prevented by screening, we
used current age-specific life expectancy for the UK (GAD, 2005) to
also estimate the net change in years of life associated with each
decade of annual mammographic screening for all women and for
women with a family history of breast cancer.
RESULTS
Table 1 shows the estimated risk of radiation-induced breast
cancer mortality associated with a decade of annual screening
according to age and family history of breast cancer. A decade of
annual mammographic screening starting at age 20 years was
estimated to increase breast cancer mortality by 0.91 deaths for
every 1000 women screened, which was nearly double the estimate
of radiation-induced breast cancer mortality associated with a
decade of annual screening starting at age 40 years (0.50 per 1000
women screened, Table 1), and nearly 10 times the estimate for a
decade of screening every 3 years starting at age 50 years (0.11 per
1000 women screened). The underlying breast cancer rates are
about two to three times higher in women with one or two affected
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yfirst-degree relatives than in the general population, hence these
women were estimated to have cumulative excess risks of
radiation-induced breast cancer mortality that were approximately
two and three times higher, respectively, than the figures for all
women.
Figure 1 shows the estimated age-specific breast cancer
mortality rates in women according to their age when breast
cancer was diagnosed. It can be seen that these mortality rates are
higher the older the women are at diagnosis (rates are extremely
low for women aged 20–29 years at diagnosis and fairly low at age
30–39 years). It can also be seen that most deaths occur 5–15
years after the diagnosis of breast cancer.
Table 2 shows the estimated reduction in breast cancer mortality
associated with a decade of annual screening according to women’s
age and a family history of breast cancer. A decade of annual
mammographic screening was estimated to reduce breast cancer
mortality by 0.05 deaths per 1000 women screened starting at age
20 years compared to 0.96 per 1000 women screened starting at age
40 years, assuming a 20% mortality reduction in women screened.
Again, because of their higher underlying breast cancer rates, for
women with one or two affected first-degree relatives, these figures
were at least two and four times higher, respectively.
Figure 2A and B shows the estimated net change in breast cancer
mortality associated with a decade of annual screening according
to age and a family history of breast cancer for a 10 and 20%
reduction in breast cancer mortality, respectively, in women
screened. There was a net increase in breast cancer deaths for a
decade of annual screening starting at age 20 years or age 30 years,
i.e., the number of radiation-induced deaths was greater than the
number of deaths prevented, even for women with affected first-
degree relatives and regardless of whether a 10 or 20% reduction in
mortality was assumed. For a decade of annual screening starting
at age 40 years, there was little or no change in the net breast
cancer mortality assuming a 10% reduction in breast cancer
mortality. However, if a 20% reduction in breast cancer mortality
was assumed, there was a net decrease in breast cancer deaths for
all women and for women with first degree-relatives with the
disease. In this scenario, the greatest net decrease was seen for
women with two affected first-degree relatives (Figure 2B).
For all women, a net loss in years of life was estimated for a
decade of screening starting at age 20 years, and screening starting
at age 30 years was estimated to result in a net gain in years of life
if a 20% mortality reduction was assumed (Table 3). For a decade
of annual mammographic screening starting at age 40 years, net
gains in years of life were estimated for both a 10 and 20%
Table 1 Estimated cumulative number of radiation-induced breast
cancer deaths per 1000 women screened in the UK according to age at
starting decade of annual screening: all women and women with affected
first-degree relatives
Women with affected first-degree
relatives
Age at starting
decade of
screening
(years) All women
One affected
relative
Two affected
relatives
20 0.91 1.64 2.80
30 0.72 1.21 1.90
40 0.50 0.79 1.24
50
a 0.11 0.17 0.25
60
a 0.04 0.06 0.08
aEstimates for screening starting at ages 50 and 60 years are shown for comparison
and assume screening every 3 years (current practice in the UK National Health
Service Breast Screening Programme).
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Figure 1 Annual UK age-specific breast cancer mortality rates (per
100000) according to the age that women were when their breast cancer
was diagnosed (20–29 up to 60–69 years).
Table 2 Estimated reduction in breast cancer mortality per 1000 women screened in the UK according to age at starting decade of annual screening and
assuming a 10 or 20% reduction in breast cancer mortality: all women and women with affected first-degree relatives
Women with affected first-degree relatives
Age at starting decade of
screening (years)
Assumed reduction in breast
cancer mortality (%) All women One affected relative Two affected relatives
20 10 0.02 0.07 0.13
20 0.05 0.14 0.25
30 10 0.18 0.49 0.91
20 0.35 0.97 1.81
40 10 0.48 1.06 2.18
20 0.96 2.13 4.35
50
a 35 2.27 4.16 7.33
60
a 35 2.53 4.02 6.74
aEstimates for screening starting at ages 50 and 60 years are shown for comparison, and are only presented for a 35% reduction in breast cancer mortality, which is the estimated
reduction based on the mammographic screening trials (IARC, 2002).
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(7–20 years per 1000 women screened) compared with the
estimated net gain for a decade of screening starting at age 50
years (42 years per 1000 women screened).
We performed a sensitivity analysis to investigate the effect on
the estimated net change in breast cancer mortality of varying the
assumptions and parameters within a ‘feasible range’ and
compared the estimated net change in breast cancer mortality
with the estimates from the original parameter values (Table 4).
This showed that for a decade of annual screening starting at age
20 years, changing the magnitude of the ERR/Gy by one standard
error resulted in the largest % change in the estimated net change
in breast cancer mortality, whereas for a decade of annual
screening starting at age 40 years, the parameters relating to the
percent reduction in mortality associated with screening had the
greatest impact. In general, annual mammography before age 40
years did not appear to be beneficial over a wide range of
assumptions, but starting screening at age 40 years could be either
beneficial or harmful, depending on whether the mortality
reduction was assumed to be 20 or 10%.
Varying all assumptions simultaneously within their feasible
ranges gives estimates of the possible extreme values of the net
changes in breast cancer mortality (Figure 3). In particular, we
were interested in whether these extremes suggested potential
reversals in the direction of the estimated net change in breast
cancer mortality. For a decade of annual screening starting at age
20 years, the minimum estimate of the net change in breast cancer
mortality still suggested that more deaths would be induced than
prevented for all women and also for those with affected first-
degree relatives. The minimum estimates for the net change in
breast cancer mortality for a decade of annual screening starting at
age 30 years suggested at most small net decreases even with
extreme assumptions. For a decade of annual screening starting at
age 40 years, there was variation in the net change in breast cancer
mortality from small increases to large decreases. For all women, for
Table 3 Estimated years of life lost due to radiation-induced breast cancer mortality, years of life gained from prevented breast cancer deaths and net
change in years of life per 1000 women screened in the UK according to age at starting decade of annual screening: all women and women with affected
first-degree relatives
Years of life gained per 1000
women screened
Net change in years of life per
1000 women screened
Assumed mortality reduction Assumed mortality reduction
Age at starting
decade of screening
(years)
Years of life lost from radiation-
induced breast cancer per 1000
women screened 10% 20% 10% 20%
20 All women 16 1 2  15  14
One affected relative 32 3 7  28  25
Two affected relatives 60 6 12  54  48
30 All women 10 6 13  42
One affected relative 18 18 35 0 17
Two affected relatives 31 33 66 2 35
40 All women 5 12 25 7 20
One affected relative 8 29 57 20 49
Two affected relatives 14 59 118 45 104
50 All women 1 — 43
a —4 2
a
One affected relative 1 — 80
a —7 9
a
Two affected relatives 2 — 144
a — 142
a
60 All women 1 — 32
a —3 1
a
One affected relative 0 — 51
a —5 1
a
Two affected relatives 0 — 86
a —8 6
a
aEstimates for screening every 3 years starting at ages 50 and 60 years are shown for comparison, and are only presented for a 35% reduction in breast cancer mortality, which is
the estimated reduction based on the mammographic screening trials (IARC, 2002).
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Figure 2 Estimated net change in breast cancer deaths per 1000 women
screened in the UK according to age at starting decade of annual screening:
all women and women with affected first degree-relatives. (A) Assuming a
10% mortality reduction, and (B) assuming a 20% mortality reduction.
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a net increase in breast cancer mortality of 0.50 to a net decrease of
0.88 per 1000 women screened. The ranges of the estimates were
widest for women with two affected first-degree relatives, suggesting
that the results were most uncertain for this group.
DISCUSSION
Our estimates suggest that for all women a decade of annual
mammographic screening starting at age 20 years would cause
more radiation-induced breast cancer deaths than it prevents, and
starting at age 30 years it is unlikely to result in a net reduction in
breast cancer mortality. However, a decade of annual screening
starting at age 40 years could result in a material net decrease in
breast cancer mortality if, among women screened, breast cancer
mortality is reduced by about 20% or more. If the mortality
reduction is 10% in women screened, then a decade of annual
screening starting at age 40 years may have little or no net benefit.
Results for women with first-degree relatives with breast cancer
were generally in the same direction but, because their background
incidence rates are higher, the net increases or decreases were
greater.
These calculations were necessarily based upon a number of
assumptions and parameter estimates; however, the sensitivity
analysis suggested that, for the most part, the conclusions were
unlikely to be significantly altered by varying the parameters
within a feasible range. One exception was for screening starting at
age 40 years for all women, where the direction of the net effect was
altered by varying the assumptions, however the magnitude of the
net effects were modest eitherway.
In this paper, we have focused on the comparison of the
radiation-induced breast cancer deaths with the number of breast
cancer deaths prevented by screening. However, the radiation-
induced cancers are likely to occur later in life, on average, than
the deaths that are prevented by screening. Therefore, we also
compared the years of life lost and gained by each decade of
mammographic screening. The conclusions from these analyses
were generally similar to those from the analysis of numbers of
deaths, with the exception of estimated small net gains in years of
life for a decade of annual screening starting at age 30 years for all
women if a 20% mortality reduction from screening was assumed,
and also for all women for a decade of screening starting at age
40 years if a 10% mortality reduction was assumed (net gain¼2
and 7 years of life per 1000 women screened, respectively).
In our calculations we did not assume that women attend for
regular screening after the specific decade of interest, because the
question under investigation was the net effect of each decade of
screening. The reason for this is that we do not think that
screening could be recommended to a certain age group on the
basis of guaranteed future screening attendance. Future screening
attendance could reduce the magnitude of the risk of radiation-
induced breast cancer mortality, if some of these cancers were
detected by screening. Therefore, we investigated the effect on the
estimated risk of radiation-induced breast cancer mortality of
assuming 100% future screening attendance by increasing the
breast cancer survival probabilities by 10 or 20% for screening
before age 50 years and by 35% after age 50 years. For a 20%
mortality reduction due to a decade of annual screening, assuming
100% future screening attendance reduced the net increase in breast
cancer deaths from 0.86 to 0.62 per 1000 women screened starting
at age 20 years, from 0.37 to 0.16 starting at age 30 years, and for
starting at age 40 years this changed the net decrease from 0.46 to
0.64 per 1000 women screened. Therefore, even if we assumed 100%
future screening attendance, this would be likely to alter the
magnitude of the net change, but not the direction of the result.
In our calculations we assumed women would be screened
annually with a two-view mammogram. In the UK Age trial, two-
view mammography was used for the first screen only, whereas
subsequent rounds used single-view mammography (Moss et al,
2005). The radiation dose from a single-view mammogram is
2.5mGy (Young et al, 2005) and so under this screening pattern,
the estimated risk of radiation-induced breast cancer mortality
for annual mammographic screening from age 40 to 47/48 years
would approximately be halved (0.22 breast cancer deaths per 1000
women screened). Although reducing the number of views per
screen, or the frequency of screening, will reduce the radiation risk
it may also decrease the reduction in breast cancer mortality due to
screening.
Table 4 Effect of varying the assumed values of certain parameters on the estimated net change in breast cancer deaths per 1000 women screened in the
UK according to age at starting decade of annual screening: all women
Net change in breast cancer deaths
Description and feasible range Age 20 years Age 30 years Age 40 years
Baseline scenario – original parameter values
a 0.86 0.37  0.46
Mortality reduction of 10% 0.89 0.55 0.02
% cancer deaths that were cancers detected during screening decade (720%) 0.86–0.88 0.30–0.44  0.66 to  0.27
Excess absolute risk model for radiation-induced breast cancer 0.73 0.07  0.76
ERRGy
 1 in the radiation risk model (71s.e.) 0.67–1.13 0.21–0.58  0.57 to  0.32
Breast cancer survival (720%) 0.69–1.05 0.23–0.55  0.56 to  0.33
Attained age parameter in the radiation risk model (71s.e.) 0.83–0.90 0.23–0.41  0.52 to  0.42
aAssuming a 20% reduction in breast cancer mortality.
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Figure 3 Estimates from the sensitivity analysis of the minimum and
maximum net change in breast cancer deaths per 1000 women screened in
the UK according to age at starting decade of annual screening: all women
and women with affected first-degree relatives.
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based on the linear no-threshold assumption,that is assuming the
radiation risks are linear in dose down to very low doses and that
there is no threshold dose below which there is no risk of cancer. A
recent review of the available biological and epidemiological
evidence concluded that there is direct epidemiological evidence of
an excess cancer risk from fractionated radiation doses as low as
50mGy (Brenner et al, 2003), which is approximately the dose
received from a decade of annual two-view screening mammo-
grams (45mGy). Therefore, the assumptions made in this article
about the existence of cancer risks at these low dose levels are
supported by epidemiological evidence, but the extrapolation is
necessary because it is not feasible to quantify the risks using
observational studies directly. Brenner et al (2003) also reviewed
the evidence regarding the most appropriate form of the
extrapolation and concluded that the assumption of linearity was
most consistent with the experimental evidence and, furthermore,
that alternative forms could result in larger as well as smaller risk
estimates. As Preston et al (2002) found no evidence that
fractionated exposure resulted in a lower risk of radiation-induced
breast cancer than acute exposure, a dose rate reduction
effectiveness factor was not included in these calculations.
The estimates for women with a family history of breast cancer
were based upon the assumption that the excess relative risk of
radiation-induced breast cancer per unit dose for these women is the
same as for all women, that is, that there is no supra or
submultiplicative interaction between radiation exposure and a
family history of breast cancer. However, BRCA-1 and BRCA-2
mutations appear to be associated with a reduction in efficiency of
DNA repair, which suggests that there may be an interaction between
these two risk factors, at least for this subgroup of women with a
family history of breast cancer (IARC, 2000). To date, only one study
has investigated the risk of radiation-induced breast cancer in
women with a family history of breast cancer directly, and reported
that women with a family history of breast cancer might have a
greater relative risk of radiation-induced breast cancer (Ronckers,
2003). Further research into this question is needed, because if this
were true then the radiation risks reported in this paper for women
with a family history of breast cancer could be underestimates.
The risk model that was used for these calculations was an
excess relative risk model based on a pooled analysis of three
cohorts, including two cohorts of women who were exposed to
multiple fluoroscopy examinations (Preston et al, 2002). In their
pooled analysis, Preston et al found no single excess relative or
excess absolute risk model that adequately described the risk of
radiation-induced breast cancer across all of the eight cohorts
considered. For breast cancer risk estimation in general popula-
tions, they suggested the use of their pooled excess absolute risk
model, which included four of the possible eight cohort studies.
Formal statistical comparison of the fits of the excess relative risk
and excess absolute risk models is not possible, but an informal
comparison based on deviance values suggested that the excess
relative risk model fitted the data marginally better. Furthermore,
the assumption underlying the excess absolute risk model is that
the risk of radiation-induced breast cancer is not related to the
underlying breast cancer incidence rate in the population. This is
equivalent to assuming that the relative increase in the risk of
breast cancer associated with radiation is actually lower for women
with a greater than average baseline risk of breast cancer, such as
women with a family history, than it is for other women. As
explained above, to date there is little reliable information on the
risk of radiation-induced breast cancer specifically in women with
a family history of the disease, but we do not think currently that
such an assumption is justifiable. However, in the sensitivity
analysis, we investigated the effect of using Preston et al’s pooled
excess absolute risk model for all women, and although the
radiation risk estimates were somewhat lower than those estimated
using the excess relative risk model, the conclusions were not
materially altered (Table 4).
Several previous studies have also estimated the radiation risks
associated with mammographic screening of younger women. Feig
and Hendrick (1997) estimated the risks from screening women
aged 40–49 years and, assuming mortality reductions of between
24 and 36% for screened women, concluded that the radiation risks
would be small compared to the mortality benefits. Beemsterboer
et al (1998) and Mattsson et al (2000) focused on the question of
whether to start screening all women at age 40 years rather than at
age 50 years. Both conclude that this strategy would reduce the net
reduction in breast cancer mortality. Mattsson et al also concluded
that at least a 20% annual reduction in breast cancer mortality was
necessary for the reduction in breast cancer mortality to outweigh
the radiation risks if screening starts at age 40 years. Finally, Law
and Faulkner (2001) considered the question of screening all
women younger than age 50 years and those with a family history
of breast cancer by estimating the ratio of the number of cancers
that might be detected by screening compared to the number of
cases induced by radiation from a single mammogram. The
interpretation of this ratio is much less straightforward than the
comparison of deaths induced to deaths prevented, but the authors
suggest that a ratio of 10:1 may be necessary to recommend
screening and concluded therefore that mammographic screening
should certainly not start before age 35 years.
The estimates for women with a family history of breast cancer
were for women with one or two affected first-degree relatives, but
these estimates could also be applied to other groups of women
that have a similarly increased underlying risk of breast cancer.
For example, for a woman with one first-degree relative who was
diagnosed with breast cancer before age 40 years, the conclusions
would be similar to those we have presented for women with two
affected first-degree relatives. Furthermore, although our estimates
are based on breast cancer incidence and mortality data from the
UK, the other parameters that were used in the calculations
including the radiation risk models and relative risks for a family
history of breast cancer were all based upon data from
international studies. Therefore, it is likely that our findings
would be broadly applicable to other Western populations with
broadly similar breast cancer incidence and mortality rates.
In conclusion, our estimates suggest that a decade of annual
mammographic screening before age 40 years would result in a net
increase in breast cancer deaths, and that starting at age 40 years
could result in a material net decrease in breast cancer deaths if
breast cancer mortality is reduced by about 20% or more in women
screened. Although these calculations were based on a number of
uncertain parameters, in general, the conclusions were not altered
when the parameters were varied within a feasible range.
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Appendix A
Example of the calculations for a decade of annual
mammographic screening starting at age 40 years
Radiation risk calculations The model that was used is an excess
relative risk model for the risk of radiation-induced breast cancer
incidence (Rj) at attained agej, where lj is the underlying breast
cancer incidence rate in the population of interest at the attained
age j (Preston et al, 2002 – Table 9)
Rj ¼ lj0:74
agej
50
    2 X j 10
k¼40
dk:
Here, dk is the radiation dose to the glandular breast tissue from a
two-view mammographic screen at age k, and the doses are
summed up to 10 years prior to attained age j to allow for the lag
period for the induction of cancer (assumed to be 10 years for
breast cancer).
The risk of radiation-induced breast cancer mortality was then
calculated by multiplying the risk of radiation-induced breast
cancer incidence at each age j by 1 the age-specific probability of
breast cancer survival (Mj). The cumulative risk of radiation-
induced breast cancer mortality (CLR) is defined as the sum of
these risks from age 50 to 84 years inclusive, adjusted for
competing causes of death using all cause survival probabilities
(Sj).
CLR ¼
X 84
j¼50
RjMjSj:
Mortality reduction calculations Only breast cancer deaths that
were from breast cancers diagnosed in women aged 40–49 years
could be affected by screening from age 40–49 years. To calculate
the age-specific breast cancer mortality rate for cancers that were
diagnosed between age 40 and 49 years, the breast cancer mortality
rates for women in the general UK population at age j (Bj) were
multiplied by the probability that a breast cancer death at age j was
diagnosed at ages 40–49 years (Pj). If we assume that mammo-
graphic screening reduces breast cancer mortality by 20%, then the
cumulative lifetime breast cancer mortality prevented by annual
mammographic screening from age 40–49 years (CLP)i s
calculated as
CLP ¼ 0:2
X 84
j¼40
BjPjSj:
For women with a family history of breast cancer, the breast cancer
mortality rates are multiplied by estimates of risk ratios (aj) for
breast cancer incidence or mortality (bj) for women with a
specified family history of breast cancer, either one or two first-
degree relatives with breast cancer, compared with women who
had no family history of breast cancer. For example, for women
with a family history of breast cancer, the CLP becomes
CLP ¼ 0:2
X 84
j¼40
bjBjPjSj:
Excess absolute risk model In the sensitivity analysis, the effect of
assuming an excess absolute risk model was also investigated. This
model does not assume that the risk of radiation-induced breast
cancer is proportional to the underlying breast cancer rate in the
population. In these calculations, the model for the excess risk of
radiation-induced breast cancer per Gy where agex is the age at
exposure and age is the attained age is also taken from Preston
et al (2002).
Forattainedagep50 : EAR=10000WY ¼ 10 e 0:05ðagex 25Þ age
50
   3:5
Forattainedage450 : EAR=10000WY ¼ 10 e 0:05ðagex 25Þ age
50
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